EASL: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Created on Tuesday, 08 May 2012 00:00
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Created on Friday, 04 May 2012 00:00
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- Details
- Category: HBV Treatment
- Created on Tuesday, 24 April 2012 00:00
No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Complete Coverage of the 2012 International Liver Congress
- Details
- Category: HBV Treatment
- Created on Wednesday, 25 April 2012 00:00
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.
HIVandHepatitis.com EASL 2012 conference section
EASL: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Created on Friday, 20 April 2012 00:00
A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.
More Articles...
- EASL International Liver Congress Starts This Week in Barcelona
- EASL: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- New HCV NS5A Inhibitor ACH-3102 Enters Clinical Trials, Gets FDA Fast-Track Status
- EASL: Ribavirin Dose Reduction Is Effective for Managing Anemia in Patients Using Boceprevir or Telaprevir
- EASL: MicroRNA Miravirsen Looks Safe and Effective for Genotype 1 Hepatitis C
- EASL: BI 201335 + BI 207127 + Ribavirin Shows Good Efficacy, Including Hepatitis C Patients with Cirrhosis
- EASL: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040
- EASL: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy
- EASL: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients
- EASL: Alisporivir + Ribavirin Is Effective for Hepatitis C, but Pancreatitis Remains a Concern
- EASL: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients
- EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
- EASL: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens for Hepatitis C
- EASL: International Liver Congress Focuses on Hepatitis C Treatment, Metabolic Liver Disease
- EASL: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
